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Abstract: Cardiovascular Health (CVH) metrics scores are associated with cardiovascular disease
but whether CVH scores are associated with nonalcoholic fatty liver disease (NAFLD) is uncertain.
Our aim was to investigate associations between CVH scores and development or regression of
NAFLD. A cohort study was performed in Korean adults who underwent a comprehensive health
examination. The CVH metrics were defined according to the American Heart Association Life’s
Simple 7 metrics, ranging from 0 (all metrics considered unhealthy) to 7 (all metrics considered
healthy). Fatty liver was diagnosed by ultrasound, and liver fibrosis assessed using NAFLD fibrosis
score (NFS). Among 93,500 participants without NAFLD or fibrosis at baseline, 15,899 developed
NAFLD, and 998 developed NAFLD plus intermediate/high NFS. Healthy CVH metrics were inversely
associated with NAFLD and also NAFLD with fibrosis. In time-dependent models after updating the
CVH score and confounders as time-varying covariate, the multivariable-adjusted hazard ratio (95%
confidence intervals) for incident NAFLD plus intermediate/high NFS participants with CVH metrics
score 2, 3, 4, 5, or 6–7 to those with score 0–1 were 0.86 (0.59–1.25), 0.51 (0.36–0.73), 0.44 (0.31–0.62),
0.20 (0.14–0.29) and 0.09 (0.05–0.14), respectively. Regression of NAFLD occurred in 9742/37,517
participants who had NAFLD at baseline with positive association with CVH metrics. Higher CVH
scores were significantly associated with both (a) decreased incidence of NAFLD, and (b) regression
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of existing NAFLD. Promoting adherence to ideal CVH metrics can be expected to reduce the burden
of NAFLD as well as cardiovascular disease.
Keywords: Nonalcoholic fatty liver disease; Hepatic fibrosis; Cardiovascular health metrics;
cohort study
1. Introduction
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease and includes
a spectrum from simple steatosis to non-alcoholic steatohepatitis (NASH) with varying degrees of
fibrosis and cirrhosis [1]. In addition to its liver-related complications, NAFLD is closely associated
with obesity, hypertension, type 2 diabetes, hyperlipidemia, and insulin resistance, all of which are
also risk factors for cardiovascular disease (CVD) [2]. Furthermore, NAFLD is considered hepatic
manifestation of metabolic syndrome and has been associated with an increased risk for CVD and
all-cause mortality [3,4]. There is no currently approved pharmacotherapy for NAFLD. Therefore,
lifestyle changes are the first line of primary and secondary prevention of NAFLD and associated
hepatic and extra-hepatic consequences.
In 2010, the American Heart Association (AHA) published recommendations for the general
population to reduce cardiovascular morbidity and mortality by addressing seven specific
cardiovascular health (CVH) behaviors and factors (Life’s Simple 7). The Life’s Simple 7 is a
comprehensive and easily applicable assessment tool in clinical settings to promote adherence to
healthy behaviors and comprise smoking, diet, physical activity, body mass index (BMI), blood pressure,
total cholesterol, and fasting glucose [5]. While primary prevention is about treating risk factors to
prevent CVD when risk factors arise, primordial prevention refers to avoiding the development of risk
factors in the first place [5,6]. The Life’s Simple 7 has been introduced with the definition of ideal CVH
metrics and an emphasis on the importance of primordial prevention of CVD through achievement
and maintenance of ideal CVH metrics [5,7]. Previous studies, including a meta-analysis of prospective
studies on ideal CVH metrics, have demonstrated a strong inverse association between ideal CVH
metrics and both CVD and non-CVD outcomes, including diabetes mellitus, cancer, and all-cause
mortality [8–11]. Although previous studies have shown associations between NAFLD and individual
behavioral factors, such as diet and physical activity [12], to date it remains uncertain whether ideal
CVH metrics are associated with development or regression of NAFLD.
We hypothesized that healthy CVH metrics would be associated with decreased development of
incident NAFLD and fibrosis and increased regression of NAFLD. If targeting healthy numbers of
CVH metrics (as a management/treatment strategy) was relevant to ameliorating NAFLD, focusing
on improving CVH metrics might be a good public health strategy to reduce not only CVD but also
NAFLD. Our aim was to investigate associations between CVH scores and: (a) development of incident
NAFLD and (b) regression of NAFLD in subjects with existing NAFLD at baseline.
2. Materials and methods
2.1. Study Population
This study was part of the Kangbuk Samsung Health Study, a cohort study of Korean men
and women 18 years or older who underwent annual or biennial health screening examinations at
Kangbuk Samsung Hospital Total Healthcare Centers in Seoul and Suwon, South Korea as previously
described [13]. The present analysis included all participants who underwent examinations, including
abdominal ultrasonography (US) and had information on all 7 components of Life’s Simple 7 CVH
metrics from March 1, 2011 (when food frequency questionnaires (FFQ) were added as part of the
health questionnaires) to December 2016 (n = 188,834).
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We excluded 51,369 participants at baseline for the following reasons: missing information
on alcohol intake, transabdominal ultrasonography, high sensitivity C-reactive protein (hsCRP),
homeostasis model assessment of insulin resistance (HOMA-IR), and components of NAFLD fibrosis
score (NFS) or aspartate transaminase to platelet ratio index (APRI); alcohol intake ≥ 30 g/day for men
and ≥ 20 g/day for women [1,14]; a history of cancer; known liver disease or use of medications for liver
disease; history of liver cirrhosis or findings of liver cirrhosis on ultrasonography; positive serologic
markers for hepatitis B or C virus; and use of steatogenic medications within the past year such as
valproate, amiodarone, methotrexate, tamoxifen, or corticosteroids [1]. Because some participants met
more than one exclusion criterion, 137,465 participants ultimately were eligible for this study (Figure 1).
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Figure 1. Flow diagram for the selection of study subjects. APRI, aspartate transaminase to platelet
ratio index; FFQ, food frequency questionnaires; HOMA-IR, homeostasis model assessment of insulin
resistance; hsCRP, high sensitivity C-reactive protein; NAFLD, non-alcoholic fatty liver disease; NFS,
NAFLD fibrosis score; US, ultrasonography.
Out of them, 37,517 (27.3%) were identified in the NAFLD cohort at the initial examination. Out of
99,948 subjects without NAFLD at baseline, we further excluded 11,762 subjects with intermediate/high
probability of fibrosis based on NFS or APRI at baseline. The final study cohort for the analysis of
associations between CVH scores and incident NAFLD and incident NAFLD with fibrosis therefore
consisted of 93,500 subjects.
This study was approved by the Institutional Review Board of Kangbuk Samsung Hospital
(IRB No. 2018-09-031), which waived the requirement for informed consent because de-identified
retrospective data were used.
2.2. Measurements
Baseline and follow-up examinations were performed at Kangbuk Samsung Hospital Health
Screening Center clinics. Standardized, self-administered questionnaires were use to obtain data
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on demographic characteristics, lifestyle factors, medical history, and medication use, as previously
described [13].
Alcohol consumption was categorized as 0, ≤ 10, and > 10 g/day. Physical activity level was
evaluated using the validated Korean version of the International Physical Activity Questionnaire
(IPAQ) short form [15]. A self-administered food frequency questionnaire (FFQ) using 103-items was
used to evaluate usual dietary intake, which was designed and validated for use in Korea [16]. The FFQ
consists of questions on the frequency and portion size of 103-items over the previous 12 months.
A database of recipes, portion sizes, and nutrients was constructed using a food composition table
from the Korean Nutrition Society. Height, weight and blood pressures (BP) were measured by trained
nurses. Hypertension was defined as a systolic blood pressure ≥ 140 mmHg, a diastolic blood pressure
≥ 90 mmHg, or use of antihypertensive medications.
Information regarding reproductive factors was collected using self-administered, standardized
questionnaires that asked about menopausal status, frequency and regularity of menstrual periods, and
use of hormone replacement therapy and oral contraceptives. Parity was assessed from the number of
reported live and still births. Menopause was defined as amenorrhea lasting for 12 or more months;
in addition, women older than 55 years without information available regarding menopause were
considered postmenopausal.
Fasting blood tests included total cholesterol, high-density lipoprotein-cholesterol (HDL-C),
triglyceride (TG), alanine transaminase (ALT), glucose, and hsCRP. Insulin resistance was calculated
using the homeostasis model (HOMA-IR) as follows: fasting insulin (mg/dL) × fasting glucose
(mg/dL)/405.
2.3. Definition of CVH Metrics
The CVH metrics were defined according to the AHA Life Simple 7 factors [5]. Ideal CVH metrics
were defined as follows: (1) Smoking: never or former smoker; (2) Physical activity: ≥ 75 min/week of
vigorous intensity physical activity, ≥ 150 min/week of moderate or moderate plus vigorous intensity
physical activity; (3) Diet: 4 or 5 healthy dietary components as defined below; (4) Total cholesterol
< 200 mg/dL; (5) BP < 120/80 mmHg; (6) Fasting glucose < 100 mg/dL; (7) BMI < 23 kg/m2 based on
the proposed cut-off for the diagnosis of overweight or obesity in Asians [17]. The diet scores were
determined based on 5 healthy dietary components as follows: fruits and vegetables ≥ 450 g/day; fish
≥ 198 g/week; fiber-rich whole grain ≥ 85 g/day; sodium < 1500 mg/day; sugar-sweetened beverages
≤1L/week. An ideal diet score was defined as 4 or more healthy components. Korean meals usually
comprise a bowl of cooked rice with a seasoned mixed soup and multiple side dishes. The median
number of healthy diet components for CVH metrics in the subjects was 2 (interquartile range 1–2).
The ratios of carbohydrate, protein, and fat to total energy intake were 67.4%, 13.9% and 18.7%,
respectively, which approximately correspond to the recommended energy intake from carbohydrate
55%–65%, protein 7%–20% and fat 15%–30% according to the Dietary Reference Intakes for Koreans.
To calculate the CVH score, each ideal CVH component was awarded 1 point. The total ideal
CVH score is defined as the sum of the values of each of the 7 ideal CVH metrics (range 0 to 7 points).
The CVH scores were categorized as 0–1, 2, 3, 4, 5, and 6–7 because only 735 (0.53%) and 3,386 (2.46%)
subjects had scores of 0 and 7 CVH, respectively. Therefore, in summary low CVH scores would be
considered unhealthy and high CVH scores would be considered healthy.
2.4. Non-Alcoholic Fatty Liver Disease and Non-Invasive Fibrosis Indices
The diagnosis of fatty liver was made using abdominal ultrasound (US) by experienced radiologists
who were blinded to the aim of the present study and was determined using standard criteria, including
the presence of a diffuse increase in fine echoes in the liver parenchyma compared with kidney or spleen
parenchyma, deep beam attenuation, and bright vessel walls [18]. Inter-observer and intra-observer
reliability for the diagnosis of fatty liver were substantial (kappa statistic of 0.74) and excellent (kappa
statistic of 0.94), respectively [13]. We defined NAFLD as the presence of a fatty liver on ultrasonography
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in the absence of excessive alcohol consumption (a threshold < 20 g/day for women and < 30 g/day for
men) and other identifiable causes of hepatic steatosis (as described in the exclusion criteria) [1].
To assess the risk of severe NAFLD, the NFS was used. The NFS was calculated using the following
formula: NFS = −1.675 + 0.037 × age (years) + 0.094 × BMI (kg/m2) + 1.13 × impaired fasting glycemia
or diabetes (yes = 1, no = 0) + 0.99 × AST/ALT ratio − 0.013 × platelet (×109/L) − 0.66 × albumin (g/dL).
Subjects were classified into three groups according to probability of advanced liver fibrosis: high (NFS
> 0.676), intermediate (NFS: 0.676 to −1.455), and low (NFS < −1.455) [19]. In a sensitivity analysis,
APRI was used and calculated according to the following formula: APRI = 100× (AST/upper limit
of normal)/platelet count (×109/L). Based on the probability of advanced fibrosis, subjects were also
categorized as: high (APRI > 1.5), intermediate (APRI: 0.5 to 1.5), and low (APRI < 0.5).
2.5. Statistical Analyses
Descriptive statistics were used to summarize the participants’ characteristics according to the
number of CVH metrics. To determine linear trends of incidence, the number of categories was used
as a continuous variable and tested on each model.
We examined the association between CVH scores and the development and regression of NAFLD.
The primary endpoint was development of NAFLD and the development of NAFLD with fibrosis
based on NFS. Due to the very small number of participants who developed NAFLD with a high
probability of advanced fibrosis (NFS > 0.676) during follow-up, we combined the intermediate and
high fibrosis scores and used NAFLD with intermediate/high fibrosis scores (≥ −1.455) as an endpoint.
We also evaluated the association between ideal CVH metrics and NAFLD regression.
The follow-up duration for each participant extended from the baseline exam until development
of the endpoint or the last health exam conducted prior to December 31, 2016, whichever came first.
Incidence rates were calculated as the number of incident cases divided by person-years of follow-up.
Since the development or regression of NAFLD was known to have developed between the two visits,
but the precise time at which it occurred was not known, we used a parametric proportional hazard
model to account for this type of interval censoring [20]. In these models, the baseline hazard function
was parameterized with restricted cubic splines in log time with four degrees of freedom.
We used parametric proportional hazards models to estimate the hazard ratios (HRs) with 95%
confidence intervals (CIs) for the development of incident NAFLD or regression of existing NAFLD.
We initially adjusted for age and sex. Model 1 was further adjusted for study center (Seoul, Suwon),
year of screening exam, alcohol intake, educational level, history of hypertension, and history of CVD.
Model 2 was further adjusted for HOMA-IR and hsCRP. To evaluate the effects of changes in CVH
scores and other covariates during the follow-up period, we performed additional analyses introducing
the CVH scores and other factors as time-varying covariates in the models.
Statistical analyses were carried out using STATA version 15.0 (StataCorp LP, College Station, TX,
USA). All P values < 0.05 were considered statistically significant.
3. Results
In 93,500 participants without NAFLD at baseline, the mean (standard deviation (SD)) age was 36.1
(6.4) years, and 42.8% of the participants were men. The proportion of those with a college education
or higher was 86.5% (Table 1). The median CVH score was 3. In 37,517 participants with NAFLD
(Table A1), the mean (SD) age was 39.2 (7.4) years, 83.7% of them were men. Increasing number of ideal
CVH metrics met was associated with younger age; female sex; less smoking; lower alcohol intake;
lower energy intake; lower BP; and lower levels of glucose, total cholesterol, LDL-C, triglycerides, ALT,
hsCRP, and HOMA-IR. Participants with higher CVH scores were more likely to have higher physical
activity and have higher HDL-C than were those with lower scores (Tables 1 and A1).
Table 2 shows the development of NAFLD and NAFLD plus intermediate/high probability
of advanced fibrosis among the NAFLD-free participants with low NFS at baseline (n = 93,500).
During 328,760.7 person-years of follow-up, 15,899 participants developed NAFLD (incidence rate,
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48.4/1,000 person-years). The median follow-up period for participants was 3.7 years (interquartile
range, 2.0–4.8, maximum 6.7). Increasing CVH scores were significantly associated with a decreased risk
for incident NAFLD in a dose-response relationship (P for trend < 0.001). The multivariable-adjusted
HR (95% CI) for development of NAFLD comparing participants with ideal CVH scores of 2, 3,
4, 5, or 6–7 to those with score of 0–1 were 0.88 (0.80–0.96), 0.74 (0.68–0.80), 0.56 (0.51–0.61), 0.39
(0.36–0.42) and 0.23 (0.21–0.25), respectively (Model 1). This association remained significant after
further adjustment for HOMA-IR and hsCRP (Model 2). During 353,133.5 person-years of follow-up,
998 participants developed NAFLD plus intermediate/high NFS (incidence rate, 2.8/1,000 person-years).
The multivariable-adjusted HR (95% CI) for development of NAFLD plus intermediate/high NFS when
comparing participants with ideal CVH metrics score of 2, 3, 4, 5, or 6–7 to those with score of 0–1
were 0.88 (0.65–1.19), 0.67 (0.50–0.89), 0.56 (0.42–0.75), 0.29 (0.21–0.39) and 0.17 (0.11–0.24), respectively.
When the association between CVH score and incident NAFLD was evaluated after updating the
CVH score and confounders as time-varying covariates, the association between CVH score and
development of NAFLD and NAFLD plus intermediate/high NFS was stronger in time-dependent
models than it was in the original analysis. In the sensitivity analysis using APRI instead of NFS, we
also found an inverse association between CVH score and NAFLD with fibrosis (Table 3).
Table 4 shows the regression of NAFLD according to CVH score in subjects with existing NAFLD
at baseline (n = 37,517). During 128,481.5 person-years of follow-up, 9,742 participants showed
regression of NAFLD (incidence rate, 75.8/1,000 person-years). The multivariable adjusted HR (95%
CI) for NAFLD regression, comparing participants with CVH scores of 2, 3, 4, 5, or 6–7 to those with
score 0–1 were 1.13 (1.04–1.23), 1.21 (1.12–1.31), 1.41 (1.30–1.53), 1.70 (1.56–1.86), and 2.28 (2.04–2.55),
respectively (Model 1). These positive associations did not change after adjusting for HOMA-IR and
the hsCRP level (Model 2). In the time-dependent analyses, the association between CVH score and
NAFLD regression was stronger than in the original analysis.
The association of CVH score with NAFLD development and regression was similarly observed
in women after further adjustment for menopausal status and oral contraceptives (Table A2).
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Table 1. Baseline characteristics by cardiovascular health metrics (CVH) scores among 93,500 participants without nonalcoholic fatty liver disease (NAFLD).
Characteristics Overall
Number of Cardiovascular Health Metrics (CVH Scores)
P for Trend
0–1 2 3 4 5 6–7
Number of participants 93,500 1240 4186 9999 19,267 29,065 29,743
Age (years) 36.1 (6.4) 37.9 (6.1) 37.6 (6.4) 37.4 (6.7) 36.7 (6.7) 35.9 (6.4) 35.0 (5.9) <0.001
Men (%) 42.8 98.0 91.6 81.8 60.2 34.5 17.3 <0.001
Alcohol intake (%) a 26.1 62.5 53.9 46.5 33.1 21.0 14.3 <0.001
Current smoker (%) 18.7 85.0 65.6 48.2 28.1 10.6 1.3 <0.001
HEPA (%) 14.9 1.9 5.4 8.3 10.4 11.6 25.2 <0.001
Education level (%) b 86.5 85.7 87.8 88.2 86.0 86.1 86.4 0.002
Diabetes (%) 0.7 3.6 2.4 1.3 0.9 0.4 0.2 <0.001
Hypertension (%) 4.5 20.8 14.6 10.4 5.8 2.8 1.1 <0.001
History of CVD (%) 0.5 0.5 0.6 0.6 0.6 0.5 0.3 <0.001
Medication for hyperlipidemia (%) 0.7 1.4 1.2 1.4 1.0 0.6 0.3 <0.001
SBP 105.2 (11.9) 123.5 (9.9) 118.9 (11.2) 114.4 (11.6) 108.5 (11.4) 103.0 (10.2) 99.4 (8.7) <0.001
DBP 67.1 (8.9) 80.4 (8.5) 76.5 (9.1) 73.2 (9.3) 69.1 (8.8) 65.6 (7.8) 63.3 (6.7) <0.001
Glucose 91.3 (9.0) 103.2 (16.0) 98.5 (13.1) 95.4 (11.0) 92.8 (9.4) 90.2 (7.3) 88.6 (6.2) <0.001
Total cholesterol 187.2 (31.5) 223.3 (27.8) 214.4 (30.1) 205.3 (31.7) 196.8 (32.0) 185.8 (30.1) 170.9 (21.7) <0.001
LDL-C (mg/dL) 112.8 (29.2) 147.3 (26.2) 140.7 (28.2) 132.4 (29.4) 122.8 (28.9) 110.6 (26.5) 96.5 (20.2) <0.001
HDL-C (mg/dL) 62.2 (14.6) 54.1 (12.0) 54.9 (12.9) 56.5 (13.6) 60.3 (14.8) 63.9 (14.9) 65.1 (13.5) <0.001
Triglycerides (mg/dL) 75 (57–103) 134.5 (101–184) 118 (88–160) 102 (77–138) 86 (65–116) 71 (56–95) 62 (50–80) <0.001
ALT (U/L) 15 (11–20) 24 (19–32) 22 (17–29) 19 (15–26) 17 (12–22) 14 (11–18) 13 (10–16) <0.001
hsCRP (mg/L) 0.3 (0.2–0.6) 0.5 (0.3–1.0) 0.5 (0.3–0.9) 0.4 (0.3–0.9) 0.4 (0.2–0.7) 0.3 (0.2–0.6) 0.3 (0.2–0.5) <0.001
HOMA-IR 1.00 (0.68–1.43) 1.44 (1.03–1.97) 1.30 (0.89–1.81) 1.18 (0.81–1.67) 1.07 (0.72–1.54) 0.97 (0.65–1.37) 0.89 (0.61–1.26) <0.001
Total energy intake (kcal/day) c 1509.6(1155.7–1896.0)
1678.1
(1397.9–2053.6)
1665.1
(1370.4–2049.8)
1647.5
(1330.6–2023.7)
1582.6
(1240.7–1965.8)
1495.9
(1149.2–1878.4)
1387.7
(1029.7–1778.9) <0.001
Data are mean (standard deviation), median (interquartile range), or percentage. a ≥ 10 g of ethanol per day. b ≥ College graduate. c Among 95,031 participants with plausible estimated
energy intake (within three standard deviations of the log-transformed mean energy intake). ALT, alanine aminotransferase; CAC, coronary artery calcification; HDL-C, high-density
lipoprotein-cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; hsCRP, high sensitivity C-reactive protein.
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Table 2. Development of NAFLD, intermediate/high probability of advanced fibrosis based on NFS, and NAFLD plus intermediate/high probability of advanced
fibrosis based on NFS by cardiovascular health metrics at baseline among 93,500 NAFLD-free participants with a low probability of advanced fibrosis at baseline.
Number of Cardiovascular
Health Metrics (CVH Scores) PY Incident Cases
Incidence Density
(per 1000 PY)
Age- and Sex-adjusted
HR (95% CI)
Multivariable-adjusted HR a (95% CI) HR (95% CI) b in a Model Using
Time-dependent VariablesModel 1 Model 2
NAFLD
0–1 4329.8 601 138.8 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
2 14468.3 1737 120.1 0.91 (0.83–1.00) 0.88 (0.80–0.96) 0.91 (0.83–0.99) 0.89 (0.80–0.99)
3 34781.4 3369 96.9 0.79 (0.72–0.86) 0.74 (0.68–0.80) 0.76 (0.70–0.83) 0.68 (0.61–0.75)
4 67564.9 4408 65.2 0.62 (0.57–0.67) 0.56 (0.51–0.61) 0.60 (0.55–0.66) 0.52 (0.47–0.57)
5 102796.4 3824 37.2 0.44 (0.40–0.48) 0.39 (0.36–0.42) 0.43 (0.39–0.47) 0.32 (0.29–0.36)
6–7 104819.9 1960 18.7 0.26 (0.24–0.29) 0.23 (0.21–0.25) 0.26 (0.23–0.28) 0.17 (0.15–0.19)
P for trend < 0.001 < 0.001 < 0.001 < 0.001
NAFLD + Intermediate/high
based on NFS
0–1 5499.5 58 10.5 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.02 (reference)
2 17594.0 153 8.7 0.86 (0.64–1.16) 0.88 (0.65–1.19) 0.91 (0.67–1.24) 0.86 (0.59–1.25)
3 40496.0 243 6.0 0.65 (0.49–0.86) 0.67 (0.50–0.89) 0.70 (0.52–0.93) 0.51 (0.36–0.73)
4 74083.1 305 4.1 0.54 (0.41–0.72) 0.56 (0.42–0.75) 0.61 (0.46–0.81) 0.44 (0.31–0.62)
5 108107.9 168 1.6 0.27 (0.20–0.37) 0.29 (0.21–0.39) 0.32 (0.24–0.44) 0.20 (0.14–0.29)
6–7 107353.0 71 0.7 0.16 (0.11–0.22) 0.17 (0.11–0.24) 0.19 (0.13–0.27) 0.09 (0.05–0.14)
P for trend < 0.001 < 0.001 < 0.001 < 0.001
a Estimated from parametric proportional hazard models. Multivariable model 1 was adjusted for age, sex, center, year of screening exam, alcohol intake, education level, history of
diabetes, history of hypertension, and history of cardiovascular disease; model 2: model 1 plus adjustment for HOMA-IR and hsCRP. b Estimated from parametric proportional hazard
models with alcohol intake and number of cardiovascular health metrics as time-dependent categorical variables and baseline age, sex, center, year of screening exam, education level,
history of diabetes, history of hypertension, and history of cardiovascular disease as time-fixed variables. BMI, body mass index; CI, confidence interval; CVH, cardiovascular health; HR,
hazards ratio; NAFLD, nonalcoholic fatty liver disease; NFS, NAFLD fibrosis score; PY, person-year.
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Table 3. Development of intermediate/high probability of advanced fibrosis based on APRI, and NAFLD plus intermediate/high probability of advanced fibrosis based
on APRI by cardiovascular health metrics at baseline among 93,500 NAFLD-free participants with a low probability of advanced fibrosis at baseline.
Number of Cardiovascular
Health Metrics (CVH Scores) PY Incident Cases
Incidence Density
(per 1000 PY)
Age- and Sex-adjusted
HR (95% CI)
Multivariable-adjusted HRa (95% CI) HR (95% CI) b in a Model Using
Time-dependent VariablesModel 1 Model 2
NAFLD + Intermediate/high
based on APRI
0–1 5600.0 22 3.9 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
2 17752.0 81 4.6 1.27 (0.79–2.03) 1.30 (0.81–2.09) 1.36 (0.85–2.19) 0.97 (0.55–1.69)
3 40718.9 116 2.8 0.86 (0.55–1.36) 0.90 (0.57–1.42) 0.95 (0.60–1.50) 0.67 (0.39–1.15)
4 74417.4 120 1.6 0.58 (0.37–0.92) 0.61 (0.39–0.97) 0.68 (0.42–1.07) 0.43 (0.25–0.74)
5 108238.4 111 1.0 0.46 (0.29–0.74) 0.50 (0.31–0.80) 0.56 (0.35–0.91) 0.32 (0.18–0.56)
6–7 107408.8 44 0.4 0.22 (0.13–0.38) 0.24 (0.14–0.41) 0.28 (0.16–0.47) 0.09 (0.04–0.17)
P for trend < 0.001 < 0.001 < 0.001 < 0.001
a Estimated from parametric proportional hazard models. Multivariable model 1 was adjusted for age, sex, center, year of screening exam, alcohol intake, education level, history of
diabetes, history of hypertension, and history of cardiovascular disease; model 2: model 1 plus adjustment for HOMA-IR and hsCRP. b Estimated from parametric proportional hazard
models with alcohol intake and number of cardiovascular health metrics as time-dependent categorical variables and baseline age, sex, center, year of screening exam, education level,
history of diabetes, history of hypertension, and history of cardiovascular disease as time-fixed variables. BMI, body mass index; CI, confidence interval; CVH, cardiovascular health; HR,
hazards ratio; NAFLD, nonalcoholic fatty liver disease; PY, person-year.
Table 4. Regression of NAFLD by cardiovascular health metrics at baseline among 37,517 participants with NAFLD.
Number of Cardiovascular
Health Metrics (CVH Scores) PY Incident Cases
Incidence Density
(per 1000 PY)
Age- and Sex-adjusted
HR (95% CI)
Multivariable-adjusted HRa (95% CI) HR (95% CI) b in a Model Using
Time-dependent VariablesModel 1 Model 2
0–1 14541.8 806 55.4 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
2 27180.7 1716 63.1 1.11 (1.02–1.21) 1.13 (1.04–1.23) 1.05 (0.97–1.14) 1.00 (0.90–1.11)
3 35923.4 2466 68.6 1.19 (1.10–1.29) 1.21 (1.12–1.31) 1.06 (0.98–1.15) 1.13 (1.03–1.24)
4 31197.3 2558 82.0 1.37 (1.27–1.49) 1.41 (1.30–1.53) 1.16 (1.07–1.26) 1.35 (1.23–1.48)
5 15538.6 1605 103.3 1.65 (1.52–1.80) 1.70 (1.56–1.86) 1.32 (1.20–1.44) 1.63 (1.47–1.80)
6–7 4099.7 591 144.2 2.23 (2.00–2.49) 2.28 (2.04–2.55) 1.64 (1.46–1.83) 2.33 (2.07–2.63)
P for trend <0.001 <0.001 <0.001 <0.001
a Estimated from parametric proportional hazard models. Multivariable model 1was adjusted for age, sex, center, year of screening exam, alcohol intake, education level, history of
diabetes, history of hypertension, and history of cardiovascular disease; model 2: model 1 plus adjustment for HOMA-IR and hsCRP. b Estimated from parametric proportional hazard
models with alcohol intake and number of cardiovascular health metrics as time-dependent categorical variables and baseline age, sex, center, year of screening exam, education level,
history of diabetes, history of hypertension, and history of cardiovascular disease as time-fixed variables. BMI, body mass index; CI, confidence interval; CVH, cardiovascular health; HR,
hazards ratio; NAFLD, nonalcoholic fatty liver disease; PY, person-year.
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4. Discussion
In the cohort without NAFLD at baseline, there was an inverse independent association between
the number of ideal CVH metrics and development of: (a) overall NAFLD and (b) NAFLD with
fibrosis based on non-invasive measures of liver fibrosis indices. Furthermore, in subjects with existing
NAFLD at baseline, CVH scores were independently associated with increased regression of NAFLD.
These associations were pronounced when changes in ideal CVH metrics and confounders during
follow-up were treated as time-varying covariates. Thus, our findings suggest that ideal CVH metrics
has beneficial effects for both a decrease in the development of new-onset NAFLD and improvement
of existing NAFLD over time.
As there are no licensed pharmaceutical treatments for NAFLD, a comprehensive approach
targeted at lifestyle modification remains the cornerstone of clinical management of NAFLD [1,14].
Previous studies have demonstrated that lifestyle modifications are associated with decreased incidence
of NAFLD development and progression [21–24]. These modifications include avoiding smoking,
maintaining a normal weight, losing weight (7%–10%), eating a healthy diet (e.g., Mediterranean diet),
and regular physical activity. The Mediterranean diet has been reported to be beneficial for prevention
of multiple chronic diseases including NAFLD [25]. Both Mediterranean diet and healthy dietary
component of CVH metrics are based on a food intake high in fruit and vegetables and fiber-rich
whole grains while healthy dietary component of CVH metrics, specifically designed for improving
cardiovascular health, includes a reduction in sodium intake and sugar-sweetened beverages [5].
However, most previous studies have focused on individual lifestyle factors in relation to NAFLD
development [21,22]. Similarly, health factors (BP, glucose, and cholesterol) have been suggested to be
associated with NAFLD development [14]. Multiple studies and meta-analyses have suggested the
association of metabolic comorbidities (hypertension, type 2 diabetes, hyperlipidemia and metabolic
syndrome) with NAFLD [26]. Although individual factors are well known traditional risk factors for
CVD, the AHA has introduced is as a comprehensive and easily applicable assessment tool in clinical
settings to promote adherence to healthy behaviors and ideal health factors, and not just to treat adverse
risk factors when they arise. However, at present little is known about the association between healthy
CVH metrics and development of, or regression of NAFLD. Very recently, a prospective cohort study
of 3424 middle-aged and elderly Chinese participants reported an inverse association between number
of ideal CVH metrics and development of NAFLD [27]. However, the study was limited by lack of
dietary information and its use of only six components of Life’s Simple 7 metrics [27]. Our study’s large
sample size, prospective design, repeated measures of all 7 CVH metrics components, ultrasonography
and noninvasive fibrosis score, and availability of other confounders allowed us to evaluate the impact
of ideal CVH metrics on both NAFLD development and regression. We found that higher CVH scores
were associated with a decreased risk of: (a) developing NAFLD, and (b) NAFLD with fibrosis, as
well as (c) increased regression of existing NAFLD. Our study extends the range of health outcomes
associated with a beneficial role of ideal CVH metrics in NAFLD in addition to CVD, incident cancer,
and all-cause mortality [11,28,29].
Our study has several limitations. First, abdominal ultrasonography was used to diagnose fatty
liver instead of liver biopsy. However, ultrasonography is widely used in both clinical practice and
epidemiology studies because of its acceptable accuracy in detecting fatty liver in a noninvasive
nature [30]. Second, we used non-invasive fibrosis indices to diagnose liver fibrosis in NAFLD [19].
The NAFLD fibrosis score has been developed and validated in a heterogeneous group of NAFLD
patients and correlates with advanced fibrosis confirmed by liver biopsy [19]. Third, the lifestyle
variables were collected using self-administered structured questionnaires that are used in health
checkup programs in Korea as part of the National Health Insurance plan. Therefore, measurement
errors or misclassifications could contribute to some degree of residual confounding. Finally, our
study population was relatively highly educated, young, and middle-aged Koreans, possibly limiting
generalizability to other populations from other ethnic groups or with different age, demographic, and
health behavior characteristics. On the other hand, our findings derived from a cohort of asymptomatic
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and relatively young people are less likely to have been affected by survivor bias, biases related to
comorbidities, or those related to the use of multiple medications than are older cohorts.
In conclusion, a higher number of ideal CVH metrics was independently associated with decreased
risk of incident NAFLD with and without liver fibrosis. Furthermore, higher number of ideal CVH
metrics was associated with regression of existing NAFLD. Promoting adherence to ideal CVH metrics
can provide a feasible and effective approach to prevent and treat NAFLD. This method may help
reduce the burden of NAFLD as well as other chronic diseases including CVD.
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Appendix A
Table A1. Baseline characteristics by cardiovascular health metrics among 37,517 participants with nonalcoholic fatty liver disease (NAFLD).
Characteristics Overall
Number of Cardiovascular Health Metrics (CVH Scores)
P for Trend
0–1 2 3 4 5 6–7
Number of participants 37,517 3795 7514 10,337 9448 5005 1418
Age (years) 39.2 (7.4) 39.5 (6.3) 39.5 (7.1) 39.3 (7.4) 39.1 (7.7) 38.7 (7.8) 37.9 (7.7) <0.001
Men (%) 83.7 97.2 92.7 88.2 79.4 67.3 54.2 <0.001
Alcohol intake a (%) 42.1 58.8 50.3 44.7 36.3 28.5 22.4 <0.001
Current smoker (%) 36.4 79.3 55.7 38.3 21.8 8.2 1.6 <0.001
HEPA (%) 14.3 2.1 6.1 11.2 17.5 26.8 46.3 <0.001
Education level b (%) 87.3 87.3 88.1 87.4 87.3 85.3 88.4 0.019
Diabetes (%) 7.1 14.3 10.3 7.3 4.9 2.4 1.2 <0.001
Hypertension (%) 17.0 29.4 23.5 17.8 12.9 7.4 4.8 <0.001
History of CVD (%) 1.0 0.8 1.0 1.0 1.2 0.9 0.8 0.720
Lipid lowering drug (%) 3.4 2.6 3.3 3.8 3.8 3.1 2.7 0.301
SBP 115.4 (12.1) 125.0 (10.6) 120.6 (11.7) 116.2 (11.5) 112.0 (10.5) 108.1 (9.4) 104.4 (8.9) <0.001
DBP 74.2 (9.7) 81.7 (8.8) 78.3 (9.5) 74.8 (9.2) 71.5 (8.3) 68.6 (7.3) 66.2 (6.9) <0.001
Glucose 99.4 (17.6) 110.2 (25.8) 103.8 (20.4) 99.5 (16.4) 96.1 (13.4) 93.1 (9.5) 91.1 (6.4) <0.001
Total cholesterol 205.9 (35.6) 229.3 (31.8) 219.5 (32.6) 209.0 (34.8) 197.8 (33.8) 185.5 (28.4) 175.1 (22.7) <0.001
LDL-C (mg/dL) 135.2 (32.0) 153.2 (28.6) 146.2 (30.0) 138.2 (31.9) 129.1 (30.7) 118.1 (26.1) 107.4 (22.2) <0.001
HDL-C (mg/dL) 48.5 (11.0) 46.5 (9.9) 47.4 (10.2) 48.1 (10.6) 48.9 (11.2) 50.4 (11.9) 53.2 (12.9) <0.001
Triglycerides (mg/dL) 136 (98–189) 179 (134–246) 158 (118–213) 141 (104–193) 123 (91–171) 106 (78–147) 90 (67–124) <0.001
ALT (U/L) 29 (20–44) 38 (27–56) 34 (24–51) 31 (22–46) 27 (19–40) 23 (16–34) 19 (14–29) <0.001
hsCRP (mg/L) 0.7 (0.4–1.4) 0.9 (0.5–1.8) 0.8 (0.5–1.5) 0.8 (0.4–1.4) 0.7 (0.4–1.4) 0.6 (0.3–1.2) 0.5 (0.3–0.9) <0.001
HOMA–IR 1.74 (1.20–2.51) 2.24 (1.58–3.26) 1.99 (1.39–2.85) 1.80 (1.25–2.55) 1.61 (1.11–2.29) 1.43 (1.00–1.99) 1.21 (0.85–1.73) <0.001
Total energy intake (kcal/day) c 1643.7(1307.3–2046.2)
1704.2
(1414.6–2101.5)
1699.2
(1373.9–2102.6)
1652.3
(1325.7–2055.9)
1616.2
(1268.3–2011.0)
1567.3
(1213.6–1986.8)
1515.9
(1161.2–1959.8) <0.001
Data are mean (standard deviation), median (interquartile range), or percentage. a ≥ 10 g of ethanol per day b ≥ college graduate c Among 34,779 participants with plausible estimated
energy intake (within three standard deviations from the log-transformed mean energy intake). ALT, alanine aminotransferase; CAC, coronary artery calcification; HDL-C, high-density
lipoprotein-cholesterol; hsCRP, high sensitivity C-reactive protein; HOMA-IR, homeostasis model assessment of insulin resistance.
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Table A2. Hazard ratios (95% CI) for Development of NAFLD, intermediate/high probability of
advanced fibrosis based on NFS and regression of NAFLD by cardiovascular health metrics at baseline
among women.
Number of
Cardiovascular Health
Metrics (CVH Scores)
Multivariable-adjusted HR a (95% CI)
For Development of
NAFLD
For Progression of Intermediate/High
Probability of Advanced Fibrosis Based on NFS
For Regression of
NAFLD
0–1 1.00 (reference) 1.00 (reference) 1.00 (reference)
2 1.18 (0.71–1.96) 0.65 (0.27–1.55) 0.86 (0.57–1.30)
3 0.90 (0.55–1.46) 0.50 (0.22–1.11) 0.95 (0.65–1.41)
4 0.64 (0.39–1.04) 0.33 (0.15–0.73) 1.03 (0.71–1.52)
5 0.38 (0.24–0.63) 0.13 (0.06–0.29) 1.20 (0.82–1.77)
6–7 0.21 0.13–0.34) 0.08 0.03–0.18) 1.47 (0.99–2.18)
P for trend <0.001 <0.001 <0.001
a Estimated from parametric proportional hazard models. Multivariable model 1was adjusted for age, sex, center,
year of screening exam, alcohol intake, education level, history of diabetes, history of hypertension, and history
of cardiovascular disease, HOMA-IR, hsCRP, menopause, parity and oral contraceptives. BMI, body mass index;
CI, confidence interval; CVH, cardiovascular health; HR, hazards ratio; NAFLD, nonalcoholic fatty liver disease;
PY, person-year.
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